CROI 2015: Antiretrovirals in the Pipeline: New Tenofovir and HIV Maturation Inhibitor [VIDEO]

alt

Tenofovir alafenamide, a new formulation that works as well as the current formulation but is easier on the kidneys and bones, and BMS-955176, a maturation inhibitor that prevents HIV from producing complete new infectious virus, were among the novel antiretroviral drugs discussed at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) last week in Seattle.


 

[David Wohl and Max Lataillade, CROI, February 25, 2015]

David Wohl from the University of North Carolina reported that tenofovir alafenamide (TAF) reaches higher levels in HIV-infected cells, but stays at lower levels in the blood, resulting in less drug exposure for the kidneys, bones, and other organs. A TAF-containing coformulation suppressed HIV as well as the current Stribild coformulation containing tenofovir disoproxil fumarate (TDF), with more than 90% achieving undetectable viral load.

Max Lataillade from Bristol-Myers Squibbreported that BMS-955176 demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier investigational drug in this class.

SEE ALSO:

CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF

CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study

3/5/15

Reference

D Wohl, A Pozniak, M Thompson, et al. Tenofovir Alafenamide (TAF) in a Single-Tablet Regimen in Initial HIV-1 Therapy. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 113LB.

CHwang, D Schürmann, C Sobotha, M Lataillade, et al. Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor. 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, February 23-24, 2015. Abstract 114LB.